title: Do selective cyclo-oxygenase-2 inhibitors have a future?
abstract: The dramatic withdrawal of rofecoxib on 30 September 2004, along with safety concerns about other cyclo-oxygenase (COX)-2 inhibitors (especially valdecoxib), raises important issues for clinicians, pharmaceutical companies and regulatory authorities. Some of these are examined in this article, including: (i) was the cardiotoxicity of rofecoxib evident long before its withdrawal?; (ii) is the thrombotic hazard a class effect that is applicable to all COX-2 inhibitors?; (iii) may conventional NSAIDs also confer a risk of cardiovascular thrombosis?; and (iv) is there any future for selective COX-2 inhibitors?
authors.affiliation: Department of Rheumatology, Pellegrin Hospital, Victor Segalen University, Bordeaux, France. bernard.bannwarth@u-bordeaux2.fr
authors.forename: Bernard
authors.initials: B
authors.lastname: Bannwarth
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal; D002318:Cardiovascular Diseases / Q000139:chemically induced; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D006801:Humans; D011358:Product Surveillance, Postmarketing / Q000191:economics / Q000379:methods; D011720:Pyrazoles / Q000009:adverse effects; D013449:Sulfonamides / Q000009:adverse effects; D013927:Thrombosis / Q000139:chemically induced
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib
references.citation: Biochem Pharmacol. 2002 Mar 1;63(5):817-21
references.pmid: 11911832
references.citation: BMJ. 2004 Oct 16;329(7471):867-8
references.pmid: 15485938
references.citation: JAMA. 2002 May 1;287(17):2215-20
references.pmid: 11980521
references.citation: Expert Opin Investig Drugs. 2005 Apr;14 (4):521-33
references.pmid: 15882125
references.citation: N Engl J Med. 2003 Mar 6;348(10):891-9
references.pmid: 12621133
references.citation: Fundam Clin Pharmacol. 2004 Feb;18(1):125-30
references.pmid: 14748764
references.citation: JAMA. 2005 Jan 19;293(3):366-8
references.pmid: 15623849
references.citation: Med J Aust. 2004 Nov 15;181(10):524-5
references.pmid: 15540956
references.citation: N Engl J Med. 2004 Oct 21;351(17):1709-11
references.pmid: 15470192
references.citation: Lancet. 2004 Dec 4-10;364(9450):2021-9
references.pmid: 15582059
references.citation: Arch Intern Med. 2000 Apr 10;160(7):913-20
references.pmid: 10761955
references.citation: Lancet. 2004 Dec 4-10;364(9450):1995-6
references.pmid: 15582041
references.citation: N Engl J Med. 2004 Dec 23;351(26):2767
references.pmid: 15608086
references.citation: Fundam Clin Pharmacol. 2003 Feb;17(1):11-20
references.pmid: 12588626
references.citation: BMJ. 2002 Jun 1;324(7349):1287-8
references.pmid: 12039807
references.citation: Circulation. 2004 May 4;109(17):2068-73
references.pmid: 15096449
references.citation: Drug Saf. 2004;27(7):427-56
references.pmid: 15141995
references.citation: Lancet. 2004 Oct 9-15;364(9442):1287-8
references.pmid: 15474114
references.citation: Drug Saf. 2001;24(11):801-11
references.pmid: 11665868
references.citation: J Rheumatol. 2003 Apr;30(4):714-9
references.pmid: 12672188
references.citation: J Rheumatol. 1995 May;22(5):983-8
references.pmid: 8587095
references.citation: JAMA. 2001 Aug 22-29;286(8):954-9
references.pmid: 11509060
references.citation: N Engl J Med. 2004 Oct 21;351(17):1707-9
references.pmid: 15470193
references.citation: J Thorac Cardiovasc Surg. 2003 Jun;125(6):1481-92
references.pmid: 12830070
references.citation: J Rheumatol. 2003 Apr;30(4):642-5
references.pmid: 12672178
references.citation: Lancet. 2004 Aug 21-27;364(9435):639-40
references.pmid: 15325809
references.citation: N Engl J Med. 2001 Aug 9;345(6):433-42
references.pmid: 11496855
references.citation: Drug Saf. 2003;26(13):913-24
references.pmid: 14583067